| abstract |
A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combinati on with a pharmaceutically acceptable carrier. Methods of treatment are also disclosed wherein an E-type prostaglandin ligand and a COX-2 selective inhibiting compound are administered in an amount that is effective to treat or prevent an E-type prostaglandin and/or COX-2 mediated disease or conditio n. |